Table 1. Characteristics of Participating Cohorts in the Asia Cohort Consortium.
| Cohort | Participants, No.a | Baseline Survey Dates |
Follow-up, Median (Range), yb | Women, No. (%) | Age at Baseline, Median (Range), y | Diabetes, No. (%) | Deaths, No. | |
|---|---|---|---|---|---|---|---|---|
| Men | Women | |||||||
| Mainland China | ||||||||
| China National Hypertension Survey Epidemiology Follow-up Study | 138 640 | 1990-1992 | 8.2 (3.0-9.9) | 70 737 (51.0) | 54.0 (40.0-91.0) | 1400 (2.1) | 1515 (2.1) | 12 453 |
| Shanghai Cohort Study | 17 703 | 1986-1989 | 18.0 (3.0-21.1) | NA | 55.0 (35.0-76.0) | 222 (1.3) | NA | 4607 |
| Shanghai Men’s Health Study | 60 379 | 2001-2006 | 9.7 (3.0-13.4) | NA | 52.0 (40.0-75.0) | 3692 (6.1) | NA | 4346 |
| Shanghai Women’s Health Study | 74 188 | 1996-2000 | 15.3 (3.0-18.4) | 74 188 (100.0) | 50.0 (40.0-70.0) | NA | 3172 (4.3) | 6903 |
| Linxian General Population Trial Cohort | 28 532 | 1984-1987 | 23.2 (3.0-25.8) | 15 929 (55.8) | 51.0 (30.0-81.0) | 18 (0.1) | 13 (0.1) | 15 320 |
| Japan | ||||||||
| 3 Prefecture Aichi Study | 20 529 | 1985-1985 | 15.2 (3.0-15.5) | 11 048 (53.8) | 53.0 (40.0-97.0) | 554 (5.8) | 368 (3.3) | 2867 |
| Ibaraki Prefectural Health Study | 95 537 | 1993-1994 | 12.3 (3.0-12.7) | 63 222 (66.2) | 60.0 (39.0-79.0) | 1255 (3.9) | 1416 (2.2) | 9721 |
| Japan Collaborative Cohort Study | 73 351 | 1988-1990 | 14.3 (3.0-16.0) | 42 820 (58.4) | 57.0 (40.0-79.0) | 2060 (6.8) | 1833 (4.3) | 9387 |
| Japan Public Health Center-Based prospective Study 1 | 42 548 | 1990-1992 | 22.6 (3.0-23.0) | 22 255 (52.3) | 50.0 (40.0-59.0) | 1114 (5.5) | 555 (2.5) | 7069 |
| Japan Public Health Center-Based Prospective Study 2 | 55 530 | 1992-1995 | 19.7 (3.0-20.0) | 29 415 (53.0) | 55.0 (40.0-69.0) | 1980 (7.6) | 1096 (3.7) | 11 964 |
| 3 Prefecture Miyagi Study | 27 954 | 1984-1984 | 15.0 (3.0-15.0) | 15 679 (56.1) | 56.0 (40.0-98.0) | 879 (7.2) | 648 (4.1) | 5436 |
| Miyagi Cohort | 46 543 | 1990-1990 | 17.8 (3.0-17.8) | 24 311 (52.2) | 53.0 (40.0-64.0) | 1182 (5.3) | 771 (3.2) | 5340 |
| Ohsaki National Health Insurance Cohort Study | 45 217 | 1994-1994 | 13.2 (3.0-13.2) | 23 561 (52.1) | 62.0 (40.0-80.0) | 1568 (7.2) | 1357 (5.8) | 8141 |
| Life Span Study | 39 314 | 1963-1993 | 21.9 (3.0-38.9) | 20 994 (53.4) | 51.0 (30.0-97.0) | 1681 (9.2) | 1181 (5.6) | 20 073 |
| Takayama Study | 25 694 | 1992-1992 | 15.6 (3.0-15.6) | 14 217 (55.3) | 54.0 (35.0-97.0) | 840 (7.3) | 471 (3.3) | 4810 |
| Korea | ||||||||
| Korean Multi-center Cancer Cohort Study | 12 607 | 1993-2004 | 14.4 (3.0-20.5) | 7665 (60.8) | 56.0 (30.0-89.0) | 222 (4.5) | 360 (4.7) | 2260 |
| Seoul Male Cancer Cohort | 13 767 | 1992-1993 | 16.0 (3.1-16.0) | NA | 49.0 (31.0-82.0) | 423 (3.1) | NA | 836 |
| Singapore | ||||||||
| Singapore Chinese Health Study | 61 298 | 1993-1999 | 12.5 (3.0-14.9) | 34 494 (56.3) | 55.0 (43.0-83.0) | 2161 (8.1) | 3041 (8.8) | 8733 |
| Taiwan | ||||||||
| Community-Based Cancer Screening Project | 23 425 | 1991-1992 | 15.9 (3.0-16.9) | 11 703 (50.0) | 47.0 (30.0-66.0) | 318 (2.7) | 251 (2.1) | 2452 |
| Cardiovascular Disease Risk Factor Two-Township Study | 4264 | 1990-1993 | 15.7 (3.0-17.2) | 2381 (55.8) | 51.0 (30.0-91.0) | 71 (3.8) | 100 (4.2) | 741 |
| Bangladesh | ||||||||
| Health Effects for Arsenic Longitudinal Study | 8489 | 2000-2002 | 12.7 (3.0-13.5) | 4185 (49.3) | 40.0 (30.0-75.0) | 132 (3.1) | 121 (2.9) | 677 |
| India | ||||||||
| Mumbai Cohort Study | 87 042 | 1991-1997 | 5.7 (3.0-8.1) | 29 733 (34.2) | 50.0 (35.0-98.0) | 1511 (2.6) | 385 (1.3) | 4732 |
| Total | 1 002 551 | 1963-2006 | 12.6 (3.0-38.9) | 518 537 (51.7) | 54.0 (30.0-98.0) | 23 283 (4.8) | 18 654 (3.6) | 148 868 |
Abbreviation: NA, not available.
a
Includes only participants who were eligible for the current pooled analysis.
b
Median years of total follow-up time interval from study entry to the final date of last contact (end of follow-up, date of death, or loss to follow-up).